stella
beta
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE — Stella
Recruiting
Back to Sjögren's Syndrome trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(6 sites)
Australia
Sydney Eye Hospital, Sydney, New South Wales
Univ of New South Wales, Sydney, New South Wales
OTA, Brisbane, Queensland
Queensland University of Technology, Brisbane, Queensland
University of the Sunshine Coast, Maroochydore, Queensland
Show all 6 locations
View full record on ClinicalTrials.gov